AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01155011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Policy Change
Description: In order to increase the sustainability of the project, MIPARC will focus on addressing on-site policies and neighborhood factors that are barriers to physical activity. Peers and staff will conduct site inspections to identify these barriers (e.g. lack of facilities, limited opening hours, unsafe sidewalks, etc.) which will be prioritized and presented to CCRC management and community officials.
Study NCT01155011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support
Description: A binder of professionally prepared materials will be provided at the beginning of the intervention and are referred to by researchers in the group sessions and phone counseling calls. The materials provide important information to encourage knowledge, self efficacy and realistic expectations.
Study NCT01155011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored environmental resources
Description: Participants will be provided with a set of printed materials relating to the residential and neighborhood environment of their CCRC. A list of step counts for key indoor routes will be provided as well as safe walking route maps for the site an local neighborhood.
Study NCT01155011 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group educational sessions
Description: Lectures will be delivered every three weeks to match the MIPARC intervention schedule. Sessions will include topics such as medications, foot care and nutrition. Physical activity will not e discussed in these sessions but participants will receive informational pamphlets on the benefits of physical activity.
Study NCT01155011 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health check phone call
Description: For the first 3 months, control participants will also receive a health check phone call to match the individual attention paid to participants in the MIPARC sites.
Study NCT01155011 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer
Description: Participants will also keep the pedometer they wear during the baseline measurement week to satisfy any curiosity about the devices and the step entry criteria. They will be given instructions on its use but will not be taught the benefits of self-monitoring.
Study NCT00200356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone
Description: Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.
Study NCT00200356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Ozagrel
Description: Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.
Study NCT03495856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training For Chronic Pain
Description: 4-week group Mindfulness training program for adults with chronic pain
Study NCT03550521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants will be instructed to focus on the sensations of breathing. Subsequently, whenever their minds wander to distressing thoughts or emotions, they will be instructed to acknowledge those thoughts or emotions, and then bring their attention back to the sensations of breathing.
Study NCT02321670 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: End-to-end
Description: Excision of the stricture and end-to-end anastomosis of the urethra.
Study NCT02321670 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Graft
Description: Incision of stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided
Study NCT02372227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-5584 and VS-6063
Description: Starting dose of VS-5584 will be 20mg taken once daily, 3x/week of each 21 day cycle. All subjects will also receive 2x/day treatment with 400mg VS-6063 in 21 day cycles. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT03316495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAMPHLET
Description: EXPOSURE TO PAMPHLETS
Study NCT03808259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (S)-ketamine Oral Thin Film
Description: (S)-ketamine OTF sublingual formulation at a dose of 7 mg, 14 mg, and 28 mg will be administered in sequential cohorts.
Study NCT03808259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (S)-ketamine IV Infusion
Description: (S)-ketamine IV solution will be infused at a dose of less than or equal to 14mg.
Study NCT03808259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo.
Study NCT03194737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroLift System Procedure
Description: Minimally invasive procedure in patients with acute urinary retention secondary to BPH.
Study NCT02262208 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic Exercises
Description: Exercise intensity for each individual by a heart rate monitor (Polar F1 TM, Polar Electro Oy, Helsinki, Finland), and a Borg 0-10 scale used to register individuals' perceived exertion every 5 minutes throughout the experimental sessions.~Aerobic session will consist of 40 min of lower limb bicycle at 70% of the peak heart rate, as determined in the incremental exercise test.
Study NCT02262208 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Eccentric Exercise
Description: Eccentric session will consist of 40 min of one lower -limb exercises (leg press) with 6 sets of 10 repetitions at 120% of 1-RM.
Study NCT02262208 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous glucose monitoring system (Guardian, Medtronic, Northridge, USA)
Description: Subjects will be admitted to the laboratory in the morning at approximately 9:00 a.m., 24 h before the exercise session, when the glucose sensor (Sof-SensorTM, Medtronic Mini-Med, Northridge, USA) will be inserted subcutaneously. The sensor is a glucose oxidase based platinum electrode that is inserted through a needle into the subcutaneous tissue of the anterior abdominal wall, using a spring-loaded device (Senserter, Medtronic, Northridge, USA). Glucose profiles will be collected the day before (day 1), the day of (day 2), and the day following (day 3) and 40 min of exercise. Each sensor will be used continuously for up to 72 h.
Study NCT02741973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Study NCT02741973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: School sport
Study NCT04341428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 20 mg
Description: DWP14012 20 mg, tablet, orally, once daily for up to 24 weeks
Study NCT04341428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP14012 20 mg placebo
Description: DWP14012 20 mg placebo-matching tablet, orally, once daily for up to 24 weeks
Study NCT04341428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 15 mg
Description: Lansoprazole 15 mg capsule, orally, once daily for up to 24 weeks
Study NCT04341428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg Placebo
Description: Lansoprazole 15 mg Placebo capsule, orally, once daily for up to 24 weeks
Study NCT00488553 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questions about cancer risk factors, medical history, and family history of cancer.
Study NCT04286906 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: MultiDimensional Profile (MDP), Anxiety-Depression Hospital Scale (HADs), Nijmegen
Study NCT04450381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rad-67 Pulse oximeter & DCI Mini sensor
Description: Noninvasive pulse oximeter that measures hemoglobin
Study NCT02668211 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PROFEMUR Preserve Classic Femoral Components
Study NCT01962961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PharmaNAC (N-acetylcysteine)
Description: PharmaNAC is considered a nutritional supplement and can be obtained without a prescription. All participants will be asked to ingest two tablets twice per day during this trial. For those randomized to PharmaNAC 1800 mg twice daily, this will be two active tablets twice per day. For those randomized to PharmaNAC 900 mg twice daily, this will be one active tablet twice per day and one matching placebo tablet twice per day. For those randomized to placebo, this will be two matching placebo tablets twice per day.~PharmaNAC can be taken with or without food. The effervescent tablets should be dissolved in 8 oz. of water or juice prior to oral intake. Each participant will take study drug and/or matching placebo for 8 weeks (up to 60 days).
Study NCT01962961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Inactive pill that matches PharmaNAC on taste, color, and appearance.
Study NCT01962961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Inactive pill that matches PharmaNAC on taste, color, and appearance.
Study NCT00763698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuickFlex Micro Model 1258T Left Heart Lead
Description: Implantation of QuickFlex Micro 1258T left heart lead in combination with a CRT-D system.
Study NCT02190565 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Food supplement
Description: Randomized double-blind, placebo-controlled
Study NCT02190565 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Food supplement
Description: Randomized double-blind, placebo-controlled
Study NCT03695770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kit for self-diagnosis and self-treatment
Description: distribution of kits for malaria self-diagnosis and self-treatment after a training by health facilitators
Study NCT03367468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Strengthening exercises ( extrinsic and intrinsic foot muscles) Stretcthing exercises (plantar fascia, plantar flexor muscles)
Study NCT03367468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: Antero-posterior gliding, talocrural traction, metatarsal mobilization
Study NCT03859947 — intervention group
Intervention type: DEVICE
Intervention: Heated humidiﬁed high-flow nasal cannula
Description: Non-invasive ventilation with a nasal cannula
Study NCT01515644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powder based infant formula
Description: Powder based infant formula with Inulin I
Study NCT01515644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powder based infant formula
Description: Powder based infant formula with Inulin II
Study NCT01515644 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Powder based infant formula
Description: Powder based infant formula without Inulin
Study NCT03666156 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No Intervention
Study NCT00781573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel, 75 mg QD, for one year
Study NCT03541395 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GnRH antagonist
Study NCT01125488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Description: levonorgestrel-releasing intrauterine system (LNG-IUS) 52mg, duration 5 years
Study NCT01125488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist (triptorelin)
Description: GnRH agonist (triptorelin 3.75 mg, sc q28day)
Study NCT01125488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist (triptorelin)
Description: GnRH agonist (triptorelin 3.75 mg, sc q28day)
Study NCT06521528 — intervention group
Intervention type: DEVICE
Intervention: nProfiler I Stomach Cancer Assay Kit
Description: nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
Study NCT03597204 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fecal immunochemical test (FIT)
Description: Annual fecal immunochemical test (FIT) for selected high risk individuals to undergo CRC screening. And colonoscopy for those with FIT positive result
Study NCT00776919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clindamycin / benzoyl peroxide gel
Description: Once a day application to the face
Study NCT00776919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin gel
Description: Once a day application to the face
Study NCT00776919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPO gel
Description: Once a day application to the face
Study NCT00776919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle gel
Description: Once a day application to the face
Study NCT03705013 — intervention group
Intervention type: OTHER
Intervention: Cologuard
Description: Observational
Study NCT04291404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: Distraction therapy using a Virtual Reality (VR) device
Study NCT00665808 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany
Study NCT00665808 — intervention group
Intervention type: DRUG
Intervention: isophane human insulin
Description: Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany
Study NCT02704143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combination of Cyberknife with S-1
Description: Radiation therapy combined with chemotherapy
Study NCT02509117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06751979 single ascending dose
Description: PF-06751979 administered as a single dose (solution/suspension) in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF-06751979). The dose levels are 3 mg, 12 mg, 40 mg, 160 mg.
Study NCT02509117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo single dose
Description: Matched Placebo solution/suspension administered as single dose.
Study NCT02509117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06751979 multiple ascending dose
Description: PF-06751979 (solution/suspension) administered daily for 14 consecutive days to parallel cohorts. The dose levels are 5 mg, 15 mg, 50 mg.
Study NCT02509117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple dose
Description: Matched Placebo (solution/suspension)administered daily for 14 consecutive days.
Study NCT02509117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06751979 multiple dose
Description: PF-06751979 (solution/suspension) administered daily for 14 consecutive days. The dose level is 50 mg.
Study NCT02509117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-06751979 multiple dose
Description: Matched Placebo (suspension/solution) administered daily for 14 consecutive days to parallel cohorts.
Study NCT04354597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ & AZ
Description: Subjects will receive weekly HCQ 400mg PO and AZ PO 500mg X 3 Days; weekly for 16 weeks.
Study NCT03941704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pulse-based diet
Description: Low Glycemic Index
Study NCT03941704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regular diet
Description: Moderate Glycemic Index
Study NCT03163017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2D Fluoroscopy
Description: Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al i.e. 2D Fluoroscopy using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system.
Study NCT03163017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Fluoroscopy
Description: After the attending surgeon is satisfied with the reduction quality from 2D Fluoroscopy, 3D fluoroscopy using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system will be used to generate additional images to assess syndesmotic and fibular reductions.
Study NCT03535246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engineered Immune Cells
Description: Engineered immune effector cells (EIE)
Study NCT02636361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered subcutaneously (SC)
Study NCT02636361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro (Humalog)
Description: Administered SC
Study NCT01396057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. It was suitable for single use only and the content of the vial was not allowed to be split
Study NCT01396057 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Dexamethasone Implant
Description: Comparator Ozurdex® (dexamethasone) was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only.
Study NCT01396057 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection: Empty sterile syringes were provided so that masking could be maintained. Either empty syringes in the case of sham injections or pre-filled syringes in the case of ranibizumab injections were visible to the patient in the room of study drug administration
Study NCT02045641 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pleuracentesis
Description: Direct needle drainage of pleural effusions with dynamic ultrasound technique
Study NCT04110535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: IV administration over 1 minute
Study NCT04110535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: IV administration over 1 minute
Study NCT04110535 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: IV administration over 1 minute
Study NCT00194870 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: EEG
Description: computer-assisted analysis of the digitally-recorded EEG signals
Study NCT00475982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Subjects undergo a weight loss intervention prior to radical prostatectomy. The intervention includes weekly visits with the dietician, DEXA scanning, blood draws, and anthropometrics.
Study NCT00475982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Weight Loss Group
Description: These subjects do not undergo a weight loss intervention prior to radical prostatectomy. This group does undergo DEXA scanning, blood draws, and anthropometrics prior to radical prostatectomy.
Study NCT01205867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848
Description: Nasal spray solution, intranasal, single ascending doses, 1.4 - 60 μg
Study NCT00597896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole
Description: po pramipexole versus matching placebo minimum 0.125 mg bid and maximum 0.75 mg bid
Study NCT00597896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pramipexole
Description: po pramipexole versus matching placebo minimum 0.125 mg bid and maximum 0.75 mg bid
Study NCT04772833 — intervention group
Intervention type: OTHER
Intervention: Autopsy
Description: The subjects deceased will undergo an autopsy to analyze the histopathological, ultrastructural and microbiological findings, related to the COVID-19 disease.
Study NCT03730142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WXFL10030390
Description: WXFL10030390 is a tablet in the form of 0.1mg and 0.5mg, oral, once a day.
Study NCT04771091 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mesure of head-perineum distance by transperineal ultrasound
Description: A mesure of head-perineum distance by ultrasound will be realized at the beginning of maternal pushing efforts by a junior gynecologist
Study NCT02920099 — intervention group
Intervention type: OTHER
Intervention: Nutrition Literacy Assessment Instrument (NLAI)
Description: Assessment tool which combines elements of different nutrition literacy tools.
Study NCT02282241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Study NCT02282241 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01895621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Median nerve decompression at the wrist
Description: Surgical incision of the carpal ligament at the wrist and proximal hand to decompress the median nerve.
Study NCT01895621 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Median nerve decompression at the wrist
Description: Surgical incision of the carpal ligament at the wrist and proximal hand to decompress the median nerve.
Study NCT01895621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid post median nerve decompression
Description: Daily supplementation of alpha lipoic acid